Nebenwirkungen · Ifirmasta (previously Irbesartan Krka)
Ifirmasta 75 mg film-coated tablets Ifirmasta 150 mg film-coated tablets Ifirmasta 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-209844 · Präparat HOS-154383
Common: significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events. In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T17:53:00Z · SHA-256 e433703ffd9bd808c0192a313a2ee367aa7dd908ac40549e8c4904a5f65b0d76 · Passage 3ed47ccb0499e850ef4a7e7b8e17e1bbacf94f1494154263bfc6487dd76e7788 · Zeichen 3882–4358 im Abschnitt